LAG-3 Protein, Human, Recombinant (hFc & Avi), Biotinylated

Copy Product Info

Catalog No. TMPY-06931

LAG-3 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 74.73 kDa and the accession number is NP_002277.4.

LAG-3 Protein, Human, Recombinant (hFc & Avi), Biotinylated

Copy Product Info

Catalog No. TMPY-06931

Pack Size	Price	USA Warehouse	Global Warehouse
5 μg	$215	7-10 days	7-10 days
10 μg	$359	7-10 days	7-10 days
20 μg	$600	7-10 days	7-10 days
50 μg	$939	7-10 days	7-10 days
100 μg	$1,580	7-10 days	7-10 days

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse [1-2 days] Global Warehouse [5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Anti-LAG3(BMS)-IgG4 Antibody (Relatlimab) at 2 μg/mL (100 μL/well) can bind Recombinant Human LAG3 Protein (Fc & AVI Tag), Biotinylated , the EC50 is 25-75 ng/mL.
Description	LAG-3 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 74.73 kDa and the accession number is NP_002277.4.
Species	Human
Expression System	HEK293 Cells
Tag	C-hFc-Avi
Accession Number	NP_002277.4
Synonyms	lymphocyte-activation gene 3,LAG-3,CD223
Construction	A DNA sequence encoding the Human LAG3 (NP_002277.4)(Met1-Leu450) was expressed with a c-terminal AVI tagged Fc region of human IgG1 at the C-terminus (Fc-AVI). The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Leu 23
Protein Purity	≥ 90 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.
Molecular Weight	74.73 kDa (predicted); 86.4 kDa (reducing conditions)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM NaH2PO4, 150 mM NaCl, 0.1M Arg, 10% glycerol, 0.01% tween20, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	LAG3 (Lymphocyte Activating 3) is a Protein Coding gene. 2 alternatively spliced human isoforms have been reported. LAG3, also known as CD223 and Lymphocyte activation gene 3, belongs to the immunoglobulin (Ig) superfamily. The LAG3 gene contains 8 exons. It is selectively expressed in activated T and NK cells. LAG3 contains 4 extracellular Ig-like domains and has a negative regulatory function in T cells. It also acts as a new marker of T cell-induced B cell activation. As a soluble molecule, LAG3 activates antigen-presenting cells through MHC class II signaling, leading to increased antigen-specific T-cell responses in vivo. Diseases associated with LAG3 include Smoldering Myeloma and Kyphoscoliotic Heart Disease.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy